
    
      Placebo, controlled, randomized, double-blind trial with 400-1000 smoking COPD patients with
      FEV-1 < 90 % predicted normal with the use of nicotine sublingual nicotine tablets or placebo
      for 12 weeks combined with individual clinic visits with low or high intensity conducted by
      trained nurses in several centres in pulmonary clinics in Denmark. Outcome was smoking
      cessation and smoking reduction after Â½ and 1 year as self declared smoking status confirmed
      by carbon monoxide in expired air< 10 ppm. Secondary outcomes were change in body-weight,
      quality of life (SF-36 and SGRQ), symptoms, lung function, adverse events.
    
  